LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus
Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when
used individually as monotherapy in the topical suspension vehicle (betamethasone
dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension
vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris
on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This
comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol
50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also
establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of
the body (trunk and/or limbs).